Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia

Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia C β-lactamases, and class A carbapene- mases of the Klebsiella pneumoniae car- bapenemase family restoring the activity of ceftazidime against Enterobacteriaceae producing these enzymes [2, 3]. Current- ly, C/A is approved for treatment of com- plicated intra-abdominal infections when used in combination with metronidazole, as well as complicated urinary tract infec- tions [4]. Interest for utilization of C/A for CRE bacteremia is piqued due to es- tablished efficacy of cephalosporins for treatment of serious infections, limita- tions of currently available treatment op- tions, and historically poor clinical outcomes [1]. However, data in support of the use of C/A for patients with CRE bacteremia susceptible to C/A are lacking. We recently successfully treated 3 pa- tients with CRE bacteremia with C/A. All isolates demonstrated in vitro sus- ceptibility to C/A. Among the 3 patients, 2 had severe infections: 1 patient was in septic shock, and the other had suspected CRE endocarditis with persistently posi- tive blood cultures and findings of a new Ceftazidime-Avibactam for mitral valve vegetation on a transthoracic Treatment of Carbapenem- echocardiogram. Doses were adjusted Resistant Enterobacteriaceae Bacteremia according to the patients’ estimated renal function based on manufacturer TO THE EDITOR—The Centers for Disease recommendations. In 2 of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Infectious Diseases Oxford University Press

Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia

Download PDF
2 pages

Loading next page...
 
/lp/oxford-university-press/ceftazidime-avibactam-for-treatment-of-carbapenem-resistant-fmL74YEVD2

References (3)

Publisher
Oxford University Press
Copyright
The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
ISSN
1058-4838
eISSN
1537-6591
DOI
10.1093/cid/ciw491
pmid
27432841
Publisher site
See Article on Publisher Site

Abstract

C β-lactamases, and class A carbapene- mases of the Klebsiella pneumoniae car- bapenemase family restoring the activity of ceftazidime against Enterobacteriaceae producing these enzymes [2, 3]. Current- ly, C/A is approved for treatment of com- plicated intra-abdominal infections when used in combination with metronidazole, as well as complicated urinary tract infec- tions [4]. Interest for utilization of C/A for CRE bacteremia is piqued due to es- tablished efficacy of cephalosporins for treatment of serious infections, limita- tions of currently available treatment op- tions, and historically poor clinical outcomes [1]. However, data in support of the use of C/A for patients with CRE bacteremia susceptible to C/A are lacking. We recently successfully treated 3 pa- tients with CRE bacteremia with C/A. All isolates demonstrated in vitro sus- ceptibility to C/A. Among the 3 patients, 2 had severe infections: 1 patient was in septic shock, and the other had suspected CRE endocarditis with persistently posi- tive blood cultures and findings of a new Ceftazidime-Avibactam for mitral valve vegetation on a transthoracic Treatment of Carbapenem- echocardiogram. Doses were adjusted Resistant Enterobacteriaceae Bacteremia according to the patients’ estimated renal function based on manufacturer TO THE EDITOR—The Centers for Disease recommendations. In 2 of

Journal

Clinical Infectious Diseases – Oxford University Press

Published: Oct 15, 2016

There are no references for this article.